1.
Key statistics for prostate cancer. American Cancer Society; 2016.
2.
Cancer stat facts: common cancer sites. National Cancer Institute Surveillance, Epidemiology, End Results Program. National Institute of Health; 2017.
3.
Cancer stat facts: prostate cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. National Institute of Health; 2017.
4.
Higgins IT. The epidemiology of cancer of the prostate. J Chronic Dis. 1975;28:343.
PubMedCrossRef
5.
Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992;14:113–130.
PubMed
6.
Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. Cancer Metastas- Rev. 2014;33:413–427.
CrossRef
7.
Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021–1024.
PubMedCrossRef
8.
Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72–89.
PubMedPubMedCentralCrossRef
9.
Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2014;4:370.
PubMedPubMedCentralCrossRef
10.
Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T. The molecular evolution of castration-resistant prostate cancer. Eur Urol Focus. 2016;2:506–513.
PubMedCrossRef
11.
Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2:273–285.
PubMedPubMedCentral
12.
Hu J, Wang G, Sun T. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol. 2017;39:1010428317692259.
PubMed
13.
Klotz L, Toren P. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol. 2012;19(Suppl 3):S13–21.
PubMedPubMedCentral
14.
Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int. 2010;105:648–651.
PubMedCrossRef
15.
Klotz L, O’Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151–1156.
PubMedPubMedCentralCrossRef
16.
Grundker C, Emons G. The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol. 2017;8:187.
CrossRef
17.
Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res. 2013;19:3353–3359.
PubMedPubMedCentralCrossRef
18.
Crona DJ, Whang YE. Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers 2017;9:18.
19.
Liu H, Wang L, Tian J, Li J, Liu H. Molecular dynamics studies on the enzalutamide resistance mechanisms induced by androgen receptor mutations. J Cell Biochem. 2017;118:2792–2801.
PubMedCrossRef
20.
Boccardo F. Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? Crit Rev Oncol Hematol. 2000;35:121–132.
PubMedCrossRef
21.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
PubMedCrossRef
22.
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow up. J Urol. 2000;164:1579–1582.
PubMedCrossRef
23.
Cooke BA, Sullivan MH. The mechanisms of LHRH agonist action in gonadal tissues. Mol Cell Endocrinol. 1985;41:115–122.
PubMedCrossRef
24.
Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology. 2012;80:174–180.
PubMedCrossRef
25.
LUPRON DEPOT® (leuprolide acetate for depot suspension) [prescribing information]. North Chicago, IL, USA: Abbott Laboratories; 2016.
26.
ELIGARD® (leuprolide acetate for injectable suspension) [prescribing information]. Fort Collins, CO, USA: Tolmar Pharmaceuticals Inc; 2017.
27.
TRELSTAR® (triptorelin pamoate injection, powder, lyophilized, for suspension) [prescribing information]. Parsippany, NJ, USA: Actavis Pharma, Inc.; 2014.
28.
ZOLADEX® (goserelin acetate implant) 10.8 mg [prescribing information]. Lake Forest, IL, USA: TerSera Therapeutics; 2017.
29.
ZOLADEX® (goserelin acetate implant) 3.6 mg [prescribing information]. Lake Forest, IL, USA: TerSera Therapeutics; 2016.
30.
Vantas™ (histrelin implant) [prescribing information]. Newbury, NJ, USA: Valera Pharmaceuticals, Inc.; 2014.
31.
Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015;11:1465–1474.
PubMedCrossRef
32.
Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int. 2017;119:239–244.
PubMedCrossRef
33.
Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, et al. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Res Rep Urol. 2016;8:159–164.
PubMedPubMedCentral
34.
McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58:756–761.
PubMedCrossRef
35.
Kao CC, Chang YH, Wu T, Sun GH, Yu DS, Chang SY, et al. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer. J Chin Med Assoc. 2012;75:255–261.
PubMedCrossRef
36.
Dias Silva E, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, et al. Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol. 2012;44:1039–1044.
PubMedCrossRef
37.
Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S. et al. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2017;10:43–50.
PubMedPubMedCentralCrossRef
38.
Saltzstein D, McLane JA, Atkinson S, Boldt-Houle D, Renzulli JF. Biodegradable polymer-delivered, subcutaneously administered leuprolide acetate consistently achieved low nadir testosterone levels ≤5 ng/dL. 28th Annual International Prostate Cancer Update; Beaver Creek, CO.
39.
Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–132.
PubMedCrossRef
40.
Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagne C, Brun D, et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab. 1988;66:314–322.
PubMedCrossRef
41.
Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897–901.
PubMedCrossRef
42.
Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology. 2009;23:626–630.
PubMed
43.
Firmagon® (degarelix for injection) [prescribing information]. Parsippany, NJ, USA: Ferring Pharmaceuticals; 2016.
44.
Plenaxis (abarelix for injectable suspension) [Physician package insert]. Little Falls, NJ, USA: Praecis Pharmaceuticals, Inc.; 2001.
45.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.
PubMedCrossRef
46.
Soga N, Kageyama T, Ogura Y, Yamada T, Hayashi N. Clinical effect of switching from a luteinizing hormone-releasing hormone agonist to an antagonist in patients with castration-resistant prostate cancer and serum testosterone level >/=20 ng/dl. Curr Urol. 2016;9:31–35.
PubMedPubMedCentralCrossRef
47.
Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012;110:499–504.
PubMedCrossRef
48.
Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.
PubMedCrossRef
49.
Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–573.
PubMedCrossRef
50.
Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ. Abiraterone acetate and prednisone in chemotherapy-naive prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol. 2017;9:319–333.
PubMedPubMedCentralCrossRef
51.
Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32:3705–3715.
PubMedPubMedCentralCrossRef
52.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Eng J Med. 2011;364:1995–2005.
CrossRef
53.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
PubMedCrossRef
54.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Eng J Med. 2017;377:352–360.
CrossRef
55.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Eng J Med. 2017;377:338–351.
CrossRef
56.
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung DP. et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153–163.
PubMedCrossRef
57.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34:2098–2106.
PubMedCrossRef
58.
ZYTIGA® (abiraterone acetate) Tablets [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2018.
59.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med. 2012;367:1187–1197.
CrossRef
60.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Eng J Med. 2014;371:424–433.
CrossRef
61.
Xtandi® (enzalutamide). Northbrook, IL USA: Astellas Pharma US, Inc.; 2017.
62.
ERLEADA™ (apalutamide) tablets, for oral use. Highlights of prescribing information. Horsham, PA: Janssen Pharmaceutical Companies; 2018.
63.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975–985.
PubMedCrossRef
64.
MacLean DB, Shi H, Faessel HM, Saad F. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100:4579–4587.
PubMedPubMedCentralCrossRef
65.
Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.
PubMedCrossRef
66.
Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol. 2011;185:848–854.
PubMedCrossRef
67.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
CrossRefPubMed
68.
Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50:2275–2282.
PubMed
69.
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Eng J Med. 2013;368:1314–1325.
CrossRef
70.
Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, et al. Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII. Scand J Urol. 2014;48:513–522.
PubMedCrossRef
71.
Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur Urol. 2016;69:720–727.
PubMedCrossRef
72.
Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2:453–461.
PubMedPubMedCentralCrossRef
73.
Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol. 2016;39:97–106.
CrossRef
74.
Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol). 2001;13:291–295.
75.
Swerdloff RS, Walsh PC. Testosterone and oestradiol suppression of LH and FSH in adult male rats: duration of castration, duration of treatment and combined treatment. Acta Endocrinol (Copenh). 1973;73:11–21.
CrossRef
76.
Morote J, Planas J, Ramirez C, Gomez E, Raventos CX, Placer J, et al. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. BJU Int. 2010;105:481–484.
PubMedCrossRef
77.
Morote J, Ramirez C, Gomez E, Planas J, Raventos CX, de Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int. 2009;104:486–489.
PubMedCrossRef
78.
van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol. 2012;187:1601–1606.
PubMedCrossRef
79.
Morote J, Comas I, Planas J, Maldonado X, Celma A, Placer J, et al. Serum testosterone levels in prostate cancer patients undergoing luteinizing hormone-releasing hormone agonist therapy. Clin Genitourin Cancer. 2018;16(2):e491–e496.
80.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137.
CrossRefPubMed
81.
Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, et al. Testosterone in prostate cancer: the Bethesda consensus. BJU Int. 2012;110:344–352.
PubMedCrossRef
82.
Prostate cancer: NCCN guidelines for prostate cancer updated. Nat Rev Urol. 2015;12:63.
83.
Dason S, Allard CB, Wang JG, Hoogenes J, Shayegan B. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice. Can J Urol. 2014;21:28–36.
PubMed
84.
Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, et al. Nadir testosterone after long-term follow up predicts prognosis in patients with prostate cancer treated with combined androgen blockade. J Urol. 2015;194:1264–1270.
PubMedCrossRef
85.
Morote J, Orsola A, Planas J, Trilla E, Raventos CX, Cecchini L, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178(4 Pt 1):1290–1295.
PubMedCrossRef
86.
Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, et al. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. BMJ. 1985;290:185–187.
PubMedCrossRefPubMedCentral
87.
Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16:7–15.
PubMedCrossRef
88.
Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK. Degarelix Study G. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008;180:1986–1992.
PubMedCrossRef
89.
Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–813.
PubMedCrossRef
90.
Huhtaniemi IT, Dahl KD, Rannikko S, Hsueh AJ. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy. J Clin Endocrinol Metab. 1988;66:308–313.
PubMedCrossRef
91.
Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol. 2000;4:275–277.
PubMed
92.
Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, et al. Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol. 2017;35:3697–3705.
PubMedCrossRef
93.
Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35:183–191.
PubMedCrossRef
94.
Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8:118–129.
PubMedCrossRef
95.
Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33(9):1281–1289.
96.
Barkin J. Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20−24, 2015, Madrid, Spain. Can J Urol. 2015;22:7847–7852.
PubMed
97.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–295.
PubMedCrossRef
98.
Scher H, Roe M. A trial comparing cardiovascular safety of Degarelix versus Leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE). NIH U.S. National Library of Medicine; 2016.
99.
Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21:383–391.
PubMedCrossRef
100.
Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res. 2003;1:385–392.
PubMed
101.
Zhang J, Zhang S, Murtha PE, Zhu W, Hou SS, Young CY. Identification of two novel cis-elements in the promoter of the prostate-specific antigen gene that are required to enhance androgen receptor-mediated transactivation. Nucleic Acids Res. 1997;25:3143–3150.
PubMedPubMedCentralCrossRef
102.
Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol. 2007;18:1828–1833.
PubMedCrossRef
103.
Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology. 2006;68:565–569.
PubMedCrossRef
104.
Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5’ promoter region of the gene. Biochemistry. 1993;32:6459–6464.
PubMedCrossRef
105.
Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115–123.
PubMedCrossRef
106.
Heidenreich A, Porres D, Epplen R, van Erps T, Pfister D. [Change of the LHRH analogue in progressive castration-refractory prostate cancer]. Urol A. 2012;51:1282–1287.
CrossRef
107.
Morote J, Comas I, Planas J, Celma A, Ferrer R, Regis L. Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. Int J Urol. 2016;23:957–958.
PubMedCrossRef
108.
Matsumoto AM, Bremner WJ. Serum testosterone assays—accuracy matters. J Clin Endocrinol Metab. 2004;89:520–524.
PubMedCrossRef
109.
Voelcker L, Maschmann R. Study of Abiraterone Acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels. NIH U.S. National Library of Medicine; 2016.
110.
Taplin M-E. Neoadjuvant and adjuvant Abiraterone Acetate + Apalutamide prostate cancer undergoing prostatectomy. NIH U.S. National Library of Medicine; 2016.
111.
Efstathiou E. Effects of Apalutamide plus LHRH agonist or Apalutamide plus Abiraterone Acetate plus LHRH agonist for six months for prostate cancer patients at high risk for recurrence. NIH U.S. National Library of Medicine; 2017.
112.
Courtney KD. Enzalutamide and hormone therapy before, during, and after radiation for high risk localized prostate cancer. NIH U.S. National Library of Medicine; 2014.
113.
Pfizer. Safety and efficacy study of Enzalutamide plus Leuprolide in patients with nonmetastatic prostate cancer (EMBARK). NIH U.S. National Library of Medicine; 2014.
114.
Wacker M. Enzalutamide versus standard androgen deprivation therapy for the treatment hormone sensitive prostate cancer. NIH U.S. National Library of Medicine; 2014.
115.
Bayer. ODM-201 in addition to standard ADT and docetaxel in metastatic castration sensitive prostate cancer (ARASENS). NIH U.S. National Library of Medicine; 2016.
116.
Garcia, MD JA. ARN-509 and Leuprolide in intermediate and high-risk prostate cancer. NIH U.S. National Library of Medicine; 2016.
117.
Androgen receptor antagonist ARN-509 with or without Abiraterone Acetate, gonadotropin-releasing hormone analog, and Prednisone in treating patients with high-risk prostate cancer undergoing surgery. NIH U.S. National Library of Medicine; 2016.
118.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Eng J Med. 2016;375:443–453.
CrossRef
119.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and Olaparib in metastatic prostate cancer. N Eng J Med. 2015;373:1697–1708.
CrossRef
120.
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7:52810–52817.
PubMedPubMedCentral
121.
Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Kennealey GT. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology. 1996;47(1A Suppl):33–37. discussion 48−53
PubMedCrossRef
122.
Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, et al. Neoadjuvant flutamide monotherapy for locally confined prostate cancer. Int J Urol. 2003;10:190–195.
PubMedCrossRef
123.
Serretta V, Daricello G, Dispensa N, Allegro R, Pavone C, Pavone-Macaluso M. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study. BJU Int. 2003;92:545–549. discussion 549–550
PubMedCrossRef
124.
Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005;96:783–786.
PubMedCrossRef
125.
Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 1998;52:72–81.
PubMedCrossRef
126.
Verhagen PC, Wildhagen MF, Verkerk AM, Vjaters E, Pagi H, Kukk L, et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol. 2014;32:1287–1294.
PubMedCrossRef
127.
Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J, Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:93–99.
PubMedCrossRef
128.
Lundstrom EA, Rencken RK, van Wyk JH, Coetzee LJ, Bahlmann JC, Reif S, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study. Clin Drug Investig. 2009;29:757–765.
PubMedCrossRef
129.
Breul J, Lundstrom E, Purcea D, Venetz WP, Cabri P, Dutailly P, et al. Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer. Adv Ther. 2017;34:513–523.
PubMedCrossRef
130.
Wilke D, Patil N, Hollenhorst H, Bowes D, Rutledge R, Ago C. Testosterone suppression with Luteinizing hormone-releasing hormone (LHRH) agonists in patients receiving radiotherapy for prostate cancer. Pharmacotherapy. 2018;38(3):327–333.
131.
Attard G, Reid AH, A’Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–3748.
PubMedCrossRef
132.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–4571.
PubMedCrossRef
133.
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, et al. Phase 2 study of the safety and antitumor activity of Apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70:963–970.
PubMedPubMedCentralCrossRef
134.
Shore ND. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18:945–952.
PubMedCrossRef